June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Generation of Luc2-eGFP-UM Cell Lines for Pre-Clinical Studies on Metastatic Uveal Melanoma
Author Affiliations & Notes
  • Ryan P Lee
    Ophthalmology, University of Tennessee Health Science Center, Memphis, TN
  • Michelle Sims
    Pathology, University of Tennessee Health Science Center, Memphis, TN
  • Bradley T Gao
    Ophthalmology, University of Tennessee Health Science Center, Memphis, TN
  • Hans E Grossniklaus
    Ophthalmology, Emory University, Atlanta, GA
  • Lawrence M Pfeffer
    Pathology, University of Tennessee Health Science Center, Memphis, TN
  • Matthew W Wilson
    Ophthalmology, University of Tennessee Health Science Center, Memphis, TN
  • Vanessa Marie Morales
    Ophthalmology, University of Tennessee Health Science Center, Memphis, TN
    Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, TN
  • Footnotes
    Commercial Relationships Ryan Lee, None; Michelle Sims, None; Bradley Gao, None; Hans Grossniklaus, None; Lawrence Pfeffer, None; Matthew Wilson, None; Vanessa Morales, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5309. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ryan P Lee, Michelle Sims, Bradley T Gao, Hans E Grossniklaus, Lawrence M Pfeffer, Matthew W Wilson, Vanessa Marie Morales; Generation of Luc2-eGFP-UM Cell Lines for Pre-Clinical Studies on Metastatic Uveal Melanoma . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5309.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Metastatic Uveal Melanoma (UM) has no available treatment. UM is the most common primary intraocular malignancy in adults. Almost half of cases metastasize to the liver, resulting in a very poor 2-year survival, but little is known about how UM invades new tissue. Of particular interest is the ability of UM to remain dormant as sub-clinical micro-metastasis. The goal of our study was to generate UM cell lines transduced with Luciferase bioluminescent protein (Luc2) and a fluorescent reporter gene (eGFP) to investigate in vivo (1) how UM migrates to, seeds, and invades the liver and (2) the kinetics of the transition from micro-metastasis to detectable metastasis.

Methods: The UM cell lines, Mel 270, 92.1, and OMM1, were transduced with a lentiviral construct (pLenti-UBC-Luc2-EGFP). Transduced cell lines were screened using IVIS® Xenogen (Caliper Life Sciences, MA) for bioluminescence and confocal microscopy for fluorescence. Validation of the transduced cell lines was performed using flow cytometry to analyze (a) cell surface expression of ICAM-1 (CD54), ICAM-2 (CD102), VCAM-1 (CD106), ALCAM (CD166), EpCAM (CD326), and VLA-4 (CD49d), (b) cell death by Annexin V and Propidium Iodide (PI), and (c) proliferative capacity by Ki-67. Cell line authentication was performed by Genetica DNA Laboratories, Inc. (Cincinnati, OH) by comparison to published material. <br />

Results: All three UM cell lines exhibited significant bioluminescence and green fluorescence in vitro 48 hours after transduction, which was sustained through time, evidencing stable transduction. Comparing transduced to non-transduced control cells, we found no difference in (a) the cohort of surface molecules, (b) the live/dead cell ratio by Annexin V and PI, and (c) proliferative capacity by Ki-67. Authentication analysis showed cell line properties were consistent with published characterization data.

Conclusions: We have generated a valuable tool for the in vivo study of metastatic UM, allowing for extremely sensitive tracking of cancer cells in animal models. Using this non-invasive tool, we are currently performing in vivo analyses of the kinetics of UM metastasis.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×